Public Health Risks of Counterfeit Pharmaceuticals

162 views

Published on

Douglas C. Moyer, PhD, CPP is Defining the Public Health Risks of Counterfeit Pharmaceuticals in this conferences important for pharmaceutical companies

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
162
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
4
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Public Health Risks of Counterfeit Pharmaceuticals

  1. 1. Defining the Public Health Risks of Counterfeit Pharmaceuticals Product Format: Audio Conference Presenter(s): Douglas C. Moyer, PhD, CPP Pharmaceutical companies get into risk with the counterfeiting problems as it negatively impacts their brand reputation and diminishes returns on new drug development. This session ‘Defining the Public Health Risks of Counterfeit Pharmaceuticals’ on Tue, Jun 03, 2014 by Douglas C. Moyer, PhD, CPP will provide participants a full understanding of counterfeit pharmaceuticals and they’ll also be able to understand:  The diversity and complexity of counterfeiting in general and pharmaceuticals in particular  How counterfeit pharmaceuticals pose risks at both the patient and population levels  The various types of patient conditions, counterfeit types, and patient reactions will be presented.  The various risks at population levels will be presented including the potential for detection and much more… For more information, go to http://www.audioeducator.com/pharma-biotech/public-health-risks- counterfeit-problems-06-03-14.html Special Offer: Use code SAVE10 to get 10% discount. Can’t attend? Request a replay of the audio session or DVD recording

×